Beecham Group plc Credit Rating

Results 1 - 50 Of 286

Page Of 6 Next

Filter By:

Date	Document Type	Title	Source
02 Aug 2018	Sector Comment	Pharmaceuticals - Global: US drugs face heightened pricing pressure and regulatory risk	Moody's Investors Service
26 Jul 2018	Sector In-Depth	Pharmaceuticals - Global: European Investor Roundtables - Q&A Highlights	Moody's Investors Service
12 Jul 2018	Sector Comment	Generic Pharmaceuticals - US: Midyear update: Developments to watch in 2018	Moody's Investors Service
12 Jul 2018	Sector Comment	Pharmaceuticals - General & Specialty - US: Midyear update: M&A off to brisk pace globally, with more to come from US	Moody's Investors Service
12 Jul 2018	Compilation	Healthcare Quarterly: July 2018	Moody's Investors Service
11 Jul 2018	Sector In-Depth	Pharmaceuticals - Europe: Strong pipelines suggest acceleration of earnings growth into 2019	Moody's Investors Service
15 May 2018	Sector Comment	Pharmaceuticals - Global: Proposals to lower US drug prices would be credit negative, if adopted	Moody's Investors Service
08 May 2018	Sector Comment	Consumer, Tobacco and Pharmaceuticals: US: Companies invest in marijuana to learn more about its challenges and opportunities	Moody's Investors Service
20 Apr 2018	Sector In-Depth	Global Pharmaceuticals Snapshot: Pipelines still good while patent expirations will remain modest over next three years	Moody's Investors Service
19 Apr 2018	Outlook	Pharmaceuticals - Global: Stable outlook reflects modest earnings growth, but M&A event risk is rising	Moody's Investors Service
16 Apr 2018	Compilation	Healthcare Quarterly: April 2018	Moody's Investors Service
16 Apr 2018	Sector Comment	Branded Pharmaceuticals - US: Mergers of health plans and PBMs will target rising drug spending	Moody's Investors Service
10 Apr 2018	Compilation	Inside Japan: April 2018	Moody's Investors Service
29 Mar 2018	Sector Comment	Pharmaceuticals - Europe: Divestment of non-core assets will be a source of liquidity in 2018	Moody's Investors Service
12 Feb 2018	Sector Comment	Pharmaceuticals - Europe: M&A poses biggest downside risk to credit quality in 2018	Moody's Investors Service
23 Jan 2018	Sector In-Depth	Generic pharmaceuticals - Europe: Market growth set to continue at a steady pace; more consolidation likely in 2018	Moody's Investors Service
10 Jan 2018	Sector Comment	Pharmaceuticals - General & Specialty - US: Developments to watch: 2018	Moody's Investors Service
10 Jan 2018	Compilation	Healthcare Quarterly: January 2018	Moody's Investors Service
09 Jan 2018	Sector In-Depth	Pharmaceuticals - US: US tax reform will spur cash depletion, mainly for M&A and shareholder payouts	Moody's Investors Service
07 Dec 2017	Outlook	Healthcare – Global: 2018 outlook reflects solid demographic trends and product innovation, offset by pricing pressure and political risk (Slides)	Moody's Investors Service
04 Dec 2017	Sector Comment	Cross-Sector: CVS/Aetna cost-containment strategies would pressure other healthcare companies	Moody's Investors Service
30 Nov 2017	Sector In-Depth	Pharmaceuticals and Distributors - US: Drug manufacturers and distributors face rising risks related to the US opioid crisis	Moody's Investors Service
27 Nov 2017	Outlook	Non-financial corporates - Japan: 2018 Outlook - Moderate global economic growth will support corporate earnings (Slides)	Moody's Investors Service
20 Nov 2017	Sector In-Depth	Non-financial corporates - US: Corporate cash to rise 5% in 2017; top five cash holders remain tech companies	Moody's Investors Service
23 Oct 2017	Compilation	Healthcare Quarterly: October 2017	Moody's Investors Service
23 Oct 2017	Sector Comment	Pharmaceuticals - US : Pricing pressure, biosimilars and patent expirations will prompt cost reductions	Moody's Investors Service
19 Oct 2017	Compilation	Inside Japan: October 2017	Moody's Investors Service
04 Oct 2017	Sector Comment	Mylan N.V. and Teva Pharmaceutical Industries Ltd : Approvals of generic versions of Copaxone are credit positive for Mylan and negative for Teva	Moody's Investors Service
28 Sep 2017	Sector In-Depth	Pharmaceuticals - Global : Biosimilars update: Market adoption faces hurdles but development continues apace	Moody's Investors Service
28 Sep 2017	Outlook	Pharmaceuticals - Global: Outlook remains stable as new product growth more than offsets pricing pressure	Moody's Investors Service
27 Sep 2017	Sector In-Depth	Not-for-profit and public healthcare, Pharmaceuticals - US : Drug price increases abate, but potential 340B change would hurt hospital margins	Moody's Investors Service
20 Sep 2017	Sector In-Depth	Consumer, Healthcare and Pharmaceuticals - US: Willing and able: How companies pursue M&A without destroying their credit	Moody's Investors Service
27 Jul 2017	Compilation	Healthcare Quarterly: July 12, 2017	Moody's Investors Service
19 Jul 2017	Sector In-Depth	US Non-Financial Companies : Cash pile grows 9.2% to $1.84 trillion; tech extends lead over other sectors	Moody's Investors Service
14 Jun 2017	Compilation	Renminbi Bonds Monitor: June 2017	Moody's Investors Service
12 Jun 2017	Sector In-Depth	Pharmaceuticals – US: Risk of IPR Patent Invalidation Creates Overhang for Branded Drug Firms	Moody's Investors Service
06 Jun 2017	Sector Comment	Pharmaceuticals - Global: ASCO Data Supports Rising Use of Cancer Drugs, a Credit Positive	Moody's Investors Service
12 May 2017	Sector In-Depth	Pharmaceuticals - Europe: Solid Pipelines to Spur Revenue Growth Beyond 2017 as Patent Headwinds Abate	Moody's Investors Service
26 Apr 2017	Outlook	Pharmaceuticals - Global: Outlook Is Stable as New Products Offset Pricing and Patent Pressures	Moody's Investors Service
24 Apr 2017	Sector In-Depth	Global Pharmaceuticals Snapshot: Pipeline Quality Slips While Patent Exposures Remain Steady	Moody's Investors Service
19 Apr 2017	Compilation	Healthcare Quarterly: 17 April 2017	Moody's Investors Service
19 Apr 2017	Sector Comment	Branded Pharmaceuticals - US: Technology Partnerships Drive Future Revenue Streams	Moody's Investors Service
18 Apr 2017	Special Comment	Inside Japan (Newsletter) - April 2017	Moody's Investors Service
30 Mar 2017	Sector Comment	Pharmaceuticals - Europe : US Approval of Ocrevus Is Credit Positive for Roche, but Poses Challenges for Rivals' MS Drugs	Moody's Investors Service
17 Mar 2017	Sector In-Depth	Corporate Healthcare - US: Proposed Healthcare Bill Would Be Credit Negative, Particularly in 2020 and Beyond	Moody's Investors Service
09 Feb 2017	Sector Comment	Pharmaceuticals - Europe: Pipelines Will Be Key Credit Driver as Generics Erode Sales of Top-selling Drugs in 2017	Moody's Investors Service
07 Feb 2017	Sector Comment	Pharmaceuticals - US: Slow Growth and Plentiful Targets Will Help Drive Robust M&A in 2017	Moody's Investors Service
17 Jan 2017	Compilation	Healthcare Quarterly: January 2017	Moody's Investors Service
17 Jan 2017	Sector Comment	Branded Pharmaceuticals - US: Developments to Watch: 2017	Moody's Investors Service
17 Jan 2017	Sector Comment	Generic Pharmaceuticals - US: Developments to Watch: 2017	Moody's Investors Service

Results 1 - 50 Of 286

Page Of 6 Next

Research & Ratings

Products & Solutions

News & Events

Registered User

Not Registered Yet?

Moody's Integrity Hotline

EU

Japan

Outside of the EU and Japan